Overview


According to FutureWise analysis the market for artemisinin combination therapy is expected to register a CAGR of 8.53% from 2023-2031.

Artemisinin Combination Therapy (ACT) is a frontline treatment for uncomplicated malaria, particularly cases caused by the Plasmodium falciparum parasite, the most lethal malaria parasite species. ACT is named after its crucial ingredient, artemisinin, sourced from the sweet wormwood plant (Artemisia annua). This natural compound has a centuries-old history in traditional Chinese medicine for alleviating fever and symptoms akin to malaria. ACT is distinguished by its combination of artemisinin or its derivatives with one or more other antimalarial drugs with different action mechanisms. This combination therapy is crucial for two main reasons. First, it helps to counteract potential resistance that the malaria parasite may develop against artemisinin, a phenomenon observed in some regions. Second, the partner drugs in ACT serve to eliminate any remaining parasites in the bloodstream after artemisinin has rapidly reduced their numbers.

Artemisinin and its derivatives are known for their unique ability to rapidly reduce the number of malaria parasites in the bloodstream, making them highly effective at alleviating severe symptoms. However, because of the risk of resistance, they are typically administered with other drugs with a different mode of action.

FutureWise Market Research has published a report that provides an insightful analysis of Artemisinin Combination Therapy Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Artemisinin Combination Therapy Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.
  • Sanofi
  • Novartis A.G.
  • Cipla limited
  • Ipca Laboratories
  • Ajanta Pharma
  • Guilin Pharmaceuticals
  • Desano Holdings Ltd.
  • Mylan N.V.
  • Hovid Berhad
  • KPC Pharmaceuticals Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Artemisinin Combination Therapy Market:

  • In August 2022, Manus Bio secured its fourth grant from the Bill & Melinda Gates Foundation, totalling USD 2 million, to advance the creation of a scalable production method for the potential antimalarial compound artemisinin. This funding empowers Manus Bio to start upscaling its innovative biological process to produce the critical chemical intermediate, dihydroartemisinic acid.

  • In July 2022, India successfully cultivated the antimalarial plant 'artemisia,' which is utilized in producing artemisinin (a drug) and its derivatives. These compounds are crucial in treating acute malaria and infections caused by parasitic worms (helminths).

Malaria continues to be a critical global health issue, particularly in sub-Saharan Africa, Southeast Asia, and South America. This underscores the need for productive antimalarial solutions like ACT. ACT has shown significant efficacy in addressing uncomplicated falciparum malaria, the deadliest variant of the disease.  Its rapid clearance of parasites from the bloodstream is a key factor contributing to its extensive use. Given the emergence of resistance to older antimalarial drugs like chloroquine and sulfadoxine-pyrimethamine, ACT has now taken precedence as the primary treatment in many endemic areas. The endorsement of ACT by the World Health Organization (WHO) substantially influences its global adoption and usage. Diverse entities, including governments, non-governmental organizations, and international agencies, actively support initiatives to combat malaria, often involving the procurement and distribution of ACT.

However, there is apprehension regarding the potential development of resistance to artemisinin and its companion drugs. Incidents of artemisinin resistance in certain parts of Southeast Asia pose a significant concern for the sustained effectiveness of ACT. Various challenges in the supply chain, encompassing factors like manufacturing capabilities, sourcing of raw materials, and logistics of distribution, can impede the production and dispersal of ACT.

By Drug Type

  • Artesunate/Mefloquine
  • Artemether/Lumefantrine
  • Dihydroartemisinin/Piperaquine
  • Artesunate/Sulfadoxine-Pyrimethamine
  • Artesunate/Amodiaquine

By Route of Administration

  • Oral
  • Intravenous
  • Intramuscular

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Stores
  • Drug Stores

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. In 2022, the Middle East and Africa emerged as the dominant market segment, primarily attributed to increased investments from developed nations, a substantial patient demographic, well-established healthcare infrastructure, the significant presence of major industry stakeholders, a rise in chronic illness prevalence, and intensified research activities in this specific geographic area.
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Artemisinin Combination Therapy Market By Drug Type, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Artemisinin Combination Therapy Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Artemisinin Combination Therapy Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Artemisinin Combination Therapy Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Artemisinin Combination Therapy Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Artesunate/Mefloquine
        2. Artemether/Lumefantrine
        3. Dihydroartemisinin/Piperaquine
        4. Artesunate/Sulfadoxine-Pyrimethamine
        5. Artesunate/Amodiaquine

  • 8.   Global Artemisinin Combination Therapy Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Oral
        2. Intravenous
        3. Intramuscular

  • 9.   Global Artemisinin Combination Therapy Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospitals Pharmacies
        2. Retail Stores
        3. Drug Stores

  • 10.   North America Artemisinin Combination Therapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Artemisinin Combination Therapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Artemisinin Combination Therapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Artemisinin Combination Therapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Sanofi
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Novartis A.G.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Cipla limited
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Ipca Laboratories
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Ajanta Pharma
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Guilin Pharmaceuticals
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Desano Holdings Ltd.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Mylan N.V.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Hovid Berhad
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. KPC Pharmaceuticals Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11